GRACE Consortium cannot invalidate criticism of feeding trials

In a letter to the new EU-Commissioner Testbiotech demands access to further data

Tuesday, 18. November 2014

The EU project GRACE, has published a first response to Testbiotech’s exposure of flaws in a rat feeding study with genetically engineered maize. In an open letter to Testbiotech, Joachim Schiemann, coordinator of the GRACE Consortium, rejected the objections raised by Testbiotech. At the same time, he neither rebutted Testbiotech’s critique nor did he address the network of vested interests around the publication. In regard to the toxicological data, he mostly repeated what was already stated in the study and therefore criticised by Testbiotech.

No majority in first vote on Monsanto's genetically engineered oilseed rape

German government abstained

13 November 2014 Testbiotech has been informed by the German authorities, that no majority was reached in a vote taken on 24 October by experts from Member States of the EU on the approval for the import of Monsanto oilseed rape MON88302. The German government abstained. The Member States will now have a second vote in the next few weeks. If no majority is reached, the new EU Commission will make a decision. If authorised, the glyphosate-resistant plants will be imported as viable seeds and, in Europe, processed into feed.

Suspected manipulation in the outcome of EU research project

Evaluation of data from feeding trial with genetically engineered maize MON810 indicates negative health impact in rats

Friday, 7. November 2014

Testbiotech has today published an independent evaluation of data from feeding trials with rats that were conducted under the GRACE project funded by the EU Commission. The rats were fed over a period of 90 days with genetically engineered maize MON810, which produces an insecticidal protein. The results were published in October 2014 in the journal Archives of Toxicology. The authors conclude that there were no relevant observable toxicological effects. However, an evaluation by Testbiotech has now revealed indications of negative health impacts on kidneys, liver and pancreas.


Subscribe to testbiotech RSS